Heat Biologics(HTBX) will be an important vaccine player
Heat Biologics is a US biotechnology focused on the field of cancer immunotherapy. Previously, they have shifted their focus to try and help tackle the worldwide pandemic, COVID-19. Heat Biologics announced they will be developing a vaccine for the coronavirus with the University of Miami Miller School of Medicine. This information was disclosed March 17 in a financial filing that its COVID-19 vaccine candidate had been added to the World Health Organization’s “draft landscape” of 41 candidate vaccines. Heat Biologics has also joined the Alliance of Biosecurity, which will help secure government funding to “secure government funding to support its rapid development, production, and distribution”.
With all of this information being said, Heat Biologics has gained 34.57% while the S&P 500 is down -6.91% as of Monday. HTBX has gained $0.16 from the previous closing price of $0.47 on volume of 21,000,548 shares. Over the past year the S&P 500 has fallen -10.92% while HTBX is down -51.54%. HTBX lost -$0.68 per share the over the last 12 months.
March 19, 2020